No Data
No Data
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025
Individual Investors Who Hold 30% of Monopar Therapeutics Inc. (NASDAQ:MNPR) Gained 45%, Institutions Profited as Well
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $40
Analysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)
Monopar Therapeutics Is Maintained at Buy by HC Wainwright & Co.